Genmab a (GMAB)
Genmab develops antibody therapies, including cancer treatments, from its base in Copenhagen, Denmark. It last closed at $50.60 on Nov 20, down 1.46% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From GMAB's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 17). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on GMAB
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 37% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the Pivot S1 at $49.99, and the nearest resistance the Pivot at $50.85.
| RSI (14) | 55.23 | Middle of its range | Neutral |
| MACD | 2.37 | Below its signal line | Bearish |
| Stochastic | 6.7 | Near the bottom of its range | Oversold |
| ADX (14) | 39.9 | Trending up | |
| Williams %R | -94.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -50.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.7% | Change over 10 sessions | Bearish |
| ATR (14) | $2.03 | Typical daily range, 4.0% of price |
| RSI (14) | 72.87 | Overbought above 70 | Overbought |
| MACD | 5.89 | Above its signal line | Bullish |
| Stochastic | 72.4 | Middle of its range | Neutral |
| ADX (14) | 45.3 | Strong uptrend | |
| Williams %R | -33.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 137.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +55.8% | Change over 10 sessions | Bullish |
| ATR (14) | $3.73 | Typical daily range, 7.4% of price |
What happened before
See how GMAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GMAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options FlowPrices may be delayed
90DNo whale options trades in GMAB in the last 90 days.
Dark PoolPrices may be delayed
30DGMAB Institutional Ownership
Full report →- ▲193 buying vs 122 selling
- ▲Shares held by funds +30.8%
- ▲Funds holding +40
- ▼Superinvestors: 1 added, 3 cut
- ▼Put/call 0.01 to 0.15
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 333 | 293 | +13.7% |
| In funds' top 10 | 7 | 5 | +40.0% |
| Held by funds | – | – | – |
| New / increased | 75 / 118 | 46 / 100 | +32.2% |
| Reduced / sold out | 87 / 35 | 102 / 32 | −9.0% |
| Put/call ratio | 0.15 | 0.01 | +1668.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GMAB is in one of them and how their past GMAB trades turned out.
GMAB News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GMAB in an article yet. Here's the latest on the wider market.
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab A/s: Foreign issuer report
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the Nine Months of 2026
- Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
- Genmab Announces Rinatabart Sesutecan (Rina-S ® ) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
GMAB Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Alan ArmstrongR · OK | Buy | $1K – $15K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Jan 16, 2025 | Feb 10, 2025 | 25 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Dec 16, 2024 | Jan 14, 2025 | 29 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Jul 19, 2024 | Aug 15, 2024 | 27 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Jun 18, 2024 | Jul 9, 2024 | 21 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Genmab a
Genmab is a biopharmaceutical company based in Copenhagen, Denmark. It develops antibody therapies, including treatments for cancer, and sells some products of its own while also working with collaboration partners who commercialize certain products. The company also uses data science and artificial intelligence to help find new drug targets and biomarkers.
- Headquarters
- 1253 Copenhagen K, Denmark







